Literature DB >> 26202453

Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus.

J-S Yun1, Y-B Ahn1, K-H Song2, K-D Yoo3, Y-M Park4, H-W Kim5, S-H Ko1.   

Abstract

AIMS: We investigated the association between lipoprotein(a) [Lp(a)] level and new-onset chronic kidney disease (CKD) in patients with Type 2 diabetes.
METHODS: We conducted a prospective cohort study from March 2003 to December 2004 with a median follow-up time of 10.1 years. Patients aged 25-75 years with Type 2 diabetes and without CKD [estimated glomerular filtration rate (eGFR) ≥ 90 ml/min/1.73 m(2) ) were consecutively enrolled. The eGFR was measured at least twice every year , and new-onset CKD was defined as a decreased eGFR status of < 60 ml/min/1.73 m(2) using a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
RESULTS: Of the 862 patients who were enrolled, 560 (65.0%) completed the follow-up and 125 (22.3%) progressed to CKD. The mean age and duration of diabetes were 53.3 ± 9.6 and 7.5 ± 6.0 years, respectively. The baseline eGFR was 101.8 ± 11.3 ml/min/1.73 m(2) . After adjusting for multiple confounding factors, a Cox hazard regression analysis revealed that the third tertile of Lp(a) was significantly associated with the development of CKD during the observation period when compared with the first tertile [hazard ratio 2.12 (95% confidence interval 1.33-3.36); P = 0.001).
CONCLUSIONS: In this prospective, longitudinal, observational cohort study, we demonstrated that the Lp(a) level was an independent prognostic factor for the future development of CKD in patients with Type 2 diabetes.
© 2015 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202453     DOI: 10.1111/dme.12862

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function.

Authors:  Caoilfhionn M Connolly; Jessica Li; Daniel Goldman; Andrea Fava; Laurence Magder; Michelle Petri
Journal:  Lupus       Date:  2022-07-01       Impact factor: 2.858

Review 2.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

3.  Serum lipoprotein (a) associates with a higher risk of reduced renal function: a prospective investigation.

Authors:  Liping Xuan; Tiange Wang; Huajie Dai; Bin Wang; Jiali Xiang; Shuangyuan Wang; Hong Lin; Mian Li; Zhiyun Zhao; Jieli Lu; Yuhong Chen; Yu Xu; Weiqing Wang; Min Xu; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2020-07-23       Impact factor: 5.922

4.  Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis.

Authors:  Xiaoyan Ren; Zhihui Zhang; Zhaoli Yan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-24       Impact factor: 5.555

5.  Preprocedural Lp(a) level and ApoB/ApoA-Ι ratio and the risk for contrast-induced acute kidney injury in patients undergoing emergency PCI.

Authors:  Jun Tao; Wen Dai; Chenglin Ye; Qian Yao; Man Zhou; Yan Li
Journal:  Lipids Health Dis       Date:  2021-10-09       Impact factor: 3.876

Review 6.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

7.  Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.

Authors:  Sunny S Singh; Mardin Rashid; Aloysius G Lieverse; Florian Kronenberg; Claudia Lamina; Monique T Mulder; Yolanda B de Rijke; Eric J G Sijbrands; Mandy van Hoek
Journal:  Diabetologia       Date:  2020-03-09       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.